Email this article HORMONAL THERAPY WITH LEUPRORELIN (LUCRIN-DEPOT®) IN PATIENTS WITH PROSTATE CANCER
- Authors: Rusakov I.G.1, Alekseyev B.Y.1, Nyushko K.M.1
-
Affiliations:
- P.A. Herzen Moscow Research Institute of Oncology
- Issue: Vol 5, No 3 (2009)
- Pages: 56-60
- Section: PROSTATE CANCER
- Published: 30.09.2009
- URL: https://oncourology.abvpress.ru/oncur/article/view/267
- DOI: https://doi.org/10.17650/1726-9776-2009-5-3-56-60
- ID: 267
Cite item
Full Text
Abstract
Leuproprelin acetate (Lucrin-depot) is an efficacious and safe luteinizing hormone-releasing hormone analogue, the efficiency of which has been proven in a number of large clinical studies. The agent exhibits a sustained release, is easy-to-use and well-tolerated, and causes minimal side effects. Lucrin-depot may be recommended for use as alone and in combination with other hormonal agents in patients with prostate cancer if androgenic deprivation is indicated.
About the authors
I. G. Rusakov
P.A. Herzen Moscow Research Institute of Oncology
Email: byalekseev@mail.ru
Russian Federation
B. Ya. Alekseyev
P.A. Herzen Moscow Research Institute of Oncology
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
K. M. Nyushko
P.A. Herzen Moscow Research Institute of Oncology
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
